DuoTrav® Eye Drops As Replacement Therapy Program

Phase 4

Completed

• Conditions: Open-angle Glaucoma; Ocular Hypertension
• Interventions: Drug: DuoTrav

• Registration Number: NCT00828906
• Lead Sponsor: Alcon Research

Brief Summary

To evaluate the effectiveness of DuoTrav Eye Drops in gaining or maintaining control of target Intraocular Pressures (tIOP) in patients diagnosed with, and being treated for, open-angle glaucoma (OAG) or ocular hypertension (OH).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-01-23
• Study First Submitted QC: 2009-01-23
• Study First Posted: 2009-01-26
• Study Start: 2009-02
• Primary Completion: 2009-11
• Status Verified: 2012-07
• Last Update Submitted: 2012-09-18
• Last Update Posted: 2012-09-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 128

Inclusion Criteria

• Patients with OAG or OH for whom single agent therapy provides insufficient intraocular pressure reduction

Exclusion Criteria

• None

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
1	DuoTrav	DuoTrav

Primary Outcome Measures

Name	Time	Method
Intra Ocular Pressure	visit 1, Visits 2-3, Visits 6-8

Trial Locations

Locations (1)

Contact Alcon for Trial Locations; 🇨🇳 Bejing, China